Patient demographics and characteristics. cAS cutaneous angiosarcoma, RAS radiation associated angiosarcoma

Patient	Demographics	Pathology	Disease state	Prior therapies	Immunotherapy	Number of ICI doses	Response at 12 weeks	Duration of response to ICI	Best Overall Response	Post ICI therapies
1	32-year-old female	Primary breast AS	MetastaticSoft tissue, Bones	Gemcitabine/ Docetaxel	Axitinib + Pembrolizumab (NCT02636725)	4	Progression of disease		Progression of disease	PaclitaxelDoxorubicin/Olaratumab
2	71-year-old female	Breast RAS	Metastatic Mediastinal lymph nodes, Lung	Doxorubicin/ Olaratumab, Gemcitabine/ Docetaxel, Pazopanib	Pembrolizumab	5	Partial response	Ongoing	Partial response	N/A
3	62-year-old female	cAS	Locally advanced- face	Doxorubicin, Gemcitabine/ Docetaxel, Pazopanib, Ifosfamide, Notch Inhibitor (NCT01695005), Temozolamide/ Bevacizumab	Anti-CTLA-4 (NCT02694822)	14	Partial response	Ongoing	Complete response	None
4	68-year-old female	cAS	Metastatic Lymph nodes, Bones	IL-2/ Cyclophosphamide/ Methotrexate, Paclitaxel, Bevacizumab	Pembrolizumab	6	Partial responseb	14 weeks	Partial responseb	N/A
4	68-year-old female	cAS	Metastatic Lymph nodes, Bones		Ipilimumab/Nivolumab	8	Partial responseb	Ongoing	Partial responseb	N/A
5	89-year-old female	cAS	Multifocal- scalp	Gemcitabine, Paclitaxel, Pazopanib	Pembrolizumab	5	Partial responsea	Ongoing	Partial response	None
6	76-year-old male	cAS	Multifocal- scalp	Pazopanib/TRC105 (NCT02979899), Doxorubicin/ Cyclophosphamide/ Olaratumab, Gemcitabine/ Docetaxel	Pembrolizumab	5	Partial responsea	Ongoing	Partial response	N/A
7	65-year-old male	cAS	Multifocal- nose	Doxorubicin/ Ifosfamide, Doxorubicin/ Cyclophosphamide, Gemcitabine/ Docetaxel	Anti-CTLA-4 (NCT02694822)	7	Progression of disease		Progression of disease	Pazopanib

^aResponse assessed by clinical exam only ^bResponse assessed by clinical exam and imaging